



COPY OF PAPERS  
ORIGINALLY FILED

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: § ATTY DCKT NO: FWLPAT015US  
**Binie V. Lipps** §  
**Frederick W. Lipps** §  
  
Serial No.: 10/047,945 § Art Unit: 1645  
  
Filed: January 14, 2002 § Examiner:  
  
For: DIAGNOSIS AND TREATMENT §  
FOR IMMUNOGLOBULIN E (IgE) §  
IMPLICATED DISORDERS §

Commissioner of Patent and Trademarks  
Washington, DC 20231

**RESPONSE**

**Honorable Commissioner:**

In response to a requirement mailed March 15, 2002 to comply with requirements for patent applications containing amino acid sequence disclosures, (copy attached) please consider the following:

The sequence listing information recorded in computer readable form and submitted with the application is identical to the written sequence listing submitted with the application. No new matter is presented.


Reconsideration and withdrawal of the requirement is requested.


Please mail correspondence to:

John R. Casperson  
PO Box 2174  
Friendswood, Texas 77549

Tel. No. 281-482-2961

Respectfully submitted:

  
John R. Casperson  
Reg. No. 28,198  
3-26-02



ORIGINALLY FILED  
COPIES OF PAPERS  
ORIGINALLY FILED

Page 1 of 1

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/047,945	01/14/2002	Binie V. Lipps	FWLPAT015US

CONFIRMATION NO. 5192  
FORMALITIES LETTER



John R. Casperson  
PO Box 2174  
Friendswood, TX 77549

Date Mailed: 03/15/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final ruiemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

**For questions regarding compliance to these requirements, please contact:**


- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice MUST be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



COPY OF PAPERS  
ORIGINALLY FILED

USCO

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

**Binie V. Lipps**

**Frederick W. Lipps**

Serial No.: 10/047,945

Filed: January 14, 2002

For: DIAGNOSIS AND TREATMENT  
FOR IMMUNOGLOBULIN E (IgE)  
IMPLICATED DISORDERS

§ ATTY DCKT NO: FWLPAT015US

§ *AP 4*  
§ Art Unit: 1645

§ Examiner:

§

Commissioner of Patent and Trademarks  
Washington, DC 20231

Sir:

Transmitted herewith for filing in the captioned application is:

(a) A Response to a Requirement dated March 15, 2002 to submit a statement that the CRF copy and the paper copy of the sequence listing are identical; and


(b) A copy of the Notice

Please mail correspondence to:

John R. Casperson  
PO Box 2174  
Friendswood, Texas 77549

Tel. No. 281-482-2961

Respectfully submitted:

  
John R. Casperson

Reg. No. 28,198

I hereby certify that this correspondence and all documents referred to herein is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

*26 March 2002*  
*John R. Casperson* *3-26-02*  
by John R. Casperson, Reg. No. 28,198 (date)